The state of the art of islet transplantation and cell therapy in type 1 diabetes

Silvia Pellegrini, Elisa Cantarelli, Valeria Sordi, Rita Nano, Lorenzo Piemonti

Research output: Contribution to journalArticle

Abstract

In patients with type 1 diabetes (T1D), pancreatic β cells are destroyed by a selective autoimmune attack and their replacement with functional insulin-producing cells is the only possible cure for this disease. The field of islet transplantation has evolved significantly from the breakthrough of the Edmonton Protocol in 2000, since significant advances in islet isolation and engraftment, together with improved immunosuppressive strategies, have been reported. The main limitations, however, remain the insufficient supply of human tissue and the need for lifelong immunosuppression therapy. Great effort is then invested in finding innovative sources of insulin-producing β cells. One old alternative with new recent perspectives is the use of non-human donor cells, in particular porcine β cells. Also the field of preexisting β cell expansion has advanced, with the development of new human β cell lines. Yet, large-scale production of human insulin-producing cells from stem cells is the most recent and promising alternative. In particular, the optimization of in vitro strategies to differentiate human embryonic stem cells into mature insulin-secreting β cells has made considerable progress and recently led to the first clinical trial of stem cell treatment for T1D. Finally, the discovery that it is possible to derive human induced pluripotent stem cells from somatic cells has raised the possibility that a sufficient amount of patient-specific β cells can be derived from patients through cell reprogramming and differentiation, suggesting that in the future there might be a cell therapy without immunosuppression.

Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalActa Diabetologica
DOIs
Publication statusAccepted/In press - Feb 29 2016

Fingerprint

Islets of Langerhans Transplantation
Cell- and Tissue-Based Therapy
Type 1 Diabetes Mellitus
Islets of Langerhans
Insulin
Immunosuppression
Stem Cells
Induced Pluripotent Stem Cells
Insulin-Secreting Cells
Human Development
Immunosuppressive Agents
Cell Differentiation
Swine
Tissue Donors
Clinical Trials
Cell Line

Keywords

  • Islet transplantation
  • Pluripotent stem cells
  • Xenotransplantation
  • β Cell replacement

ASJC Scopus subject areas

  • Endocrinology
  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

The state of the art of islet transplantation and cell therapy in type 1 diabetes. / Pellegrini, Silvia; Cantarelli, Elisa; Sordi, Valeria; Nano, Rita; Piemonti, Lorenzo.

In: Acta Diabetologica, 29.02.2016, p. 1-9.

Research output: Contribution to journalArticle

@article{f16e0eea435041a191ecc46056365fb3,
title = "The state of the art of islet transplantation and cell therapy in type 1 diabetes",
abstract = "In patients with type 1 diabetes (T1D), pancreatic β cells are destroyed by a selective autoimmune attack and their replacement with functional insulin-producing cells is the only possible cure for this disease. The field of islet transplantation has evolved significantly from the breakthrough of the Edmonton Protocol in 2000, since significant advances in islet isolation and engraftment, together with improved immunosuppressive strategies, have been reported. The main limitations, however, remain the insufficient supply of human tissue and the need for lifelong immunosuppression therapy. Great effort is then invested in finding innovative sources of insulin-producing β cells. One old alternative with new recent perspectives is the use of non-human donor cells, in particular porcine β cells. Also the field of preexisting β cell expansion has advanced, with the development of new human β cell lines. Yet, large-scale production of human insulin-producing cells from stem cells is the most recent and promising alternative. In particular, the optimization of in vitro strategies to differentiate human embryonic stem cells into mature insulin-secreting β cells has made considerable progress and recently led to the first clinical trial of stem cell treatment for T1D. Finally, the discovery that it is possible to derive human induced pluripotent stem cells from somatic cells has raised the possibility that a sufficient amount of patient-specific β cells can be derived from patients through cell reprogramming and differentiation, suggesting that in the future there might be a cell therapy without immunosuppression.",
keywords = "Islet transplantation, Pluripotent stem cells, Xenotransplantation, β Cell replacement",
author = "Silvia Pellegrini and Elisa Cantarelli and Valeria Sordi and Rita Nano and Lorenzo Piemonti",
year = "2016",
month = "2",
day = "29",
doi = "10.1007/s00592-016-0847-z",
language = "English",
pages = "1--9",
journal = "Acta Diabetologica",
issn = "0940-5429",
publisher = "Springer-Verlag Italia s.r.l.",

}

TY - JOUR

T1 - The state of the art of islet transplantation and cell therapy in type 1 diabetes

AU - Pellegrini, Silvia

AU - Cantarelli, Elisa

AU - Sordi, Valeria

AU - Nano, Rita

AU - Piemonti, Lorenzo

PY - 2016/2/29

Y1 - 2016/2/29

N2 - In patients with type 1 diabetes (T1D), pancreatic β cells are destroyed by a selective autoimmune attack and their replacement with functional insulin-producing cells is the only possible cure for this disease. The field of islet transplantation has evolved significantly from the breakthrough of the Edmonton Protocol in 2000, since significant advances in islet isolation and engraftment, together with improved immunosuppressive strategies, have been reported. The main limitations, however, remain the insufficient supply of human tissue and the need for lifelong immunosuppression therapy. Great effort is then invested in finding innovative sources of insulin-producing β cells. One old alternative with new recent perspectives is the use of non-human donor cells, in particular porcine β cells. Also the field of preexisting β cell expansion has advanced, with the development of new human β cell lines. Yet, large-scale production of human insulin-producing cells from stem cells is the most recent and promising alternative. In particular, the optimization of in vitro strategies to differentiate human embryonic stem cells into mature insulin-secreting β cells has made considerable progress and recently led to the first clinical trial of stem cell treatment for T1D. Finally, the discovery that it is possible to derive human induced pluripotent stem cells from somatic cells has raised the possibility that a sufficient amount of patient-specific β cells can be derived from patients through cell reprogramming and differentiation, suggesting that in the future there might be a cell therapy without immunosuppression.

AB - In patients with type 1 diabetes (T1D), pancreatic β cells are destroyed by a selective autoimmune attack and their replacement with functional insulin-producing cells is the only possible cure for this disease. The field of islet transplantation has evolved significantly from the breakthrough of the Edmonton Protocol in 2000, since significant advances in islet isolation and engraftment, together with improved immunosuppressive strategies, have been reported. The main limitations, however, remain the insufficient supply of human tissue and the need for lifelong immunosuppression therapy. Great effort is then invested in finding innovative sources of insulin-producing β cells. One old alternative with new recent perspectives is the use of non-human donor cells, in particular porcine β cells. Also the field of preexisting β cell expansion has advanced, with the development of new human β cell lines. Yet, large-scale production of human insulin-producing cells from stem cells is the most recent and promising alternative. In particular, the optimization of in vitro strategies to differentiate human embryonic stem cells into mature insulin-secreting β cells has made considerable progress and recently led to the first clinical trial of stem cell treatment for T1D. Finally, the discovery that it is possible to derive human induced pluripotent stem cells from somatic cells has raised the possibility that a sufficient amount of patient-specific β cells can be derived from patients through cell reprogramming and differentiation, suggesting that in the future there might be a cell therapy without immunosuppression.

KW - Islet transplantation

KW - Pluripotent stem cells

KW - Xenotransplantation

KW - β Cell replacement

UR - http://www.scopus.com/inward/record.url?scp=84959370855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959370855&partnerID=8YFLogxK

U2 - 10.1007/s00592-016-0847-z

DO - 10.1007/s00592-016-0847-z

M3 - Article

AN - SCOPUS:84959370855

SP - 1

EP - 9

JO - Acta Diabetologica

JF - Acta Diabetologica

SN - 0940-5429

ER -